FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296989445> ?p ?o ?g. }

• W2296989445 endingPage "449" @default.
• W2296989445 startingPage "440" @default.
• W2296989445 abstract "Preventing venous thromboembolism (VTE) remains an important topic in the plastic surgery community. However, there is little consensus regarding appropriate VTE prophylaxis for patients undergoing common body contouring procedures. This study compared the use of two novel oral anticoagulants (Rivaroxaban and Apixiban) vs low molecular weight heparin (LMWH) for postoperative chemical prophylaxis in body contouring plastic surgery procedures. A single center retrospective chart review of 1572 patients who underwent body contouring plastic surgery procedures from January 2012 to February 2015 was performed. Major complications associated with chemical prophylaxis were reviewed including hematomas requiring surgical evacuation, acute blood loss anemia requiring transfusions, and thrombotic or hemorrhagic events. Drug-related adverse events occurred in 1.27% (n = 20) of patients. The complications encountered by the 454 patients on LMWH consisted of 0.88% (n = 4) with hematomas requiring surgical evacuation, 0.44% (n = 2) with decreased hemoglobin requiring transfusions, and 0.22% (n = 1) with a deep vein thrombosis (DVT). The complications encountered by 703 patients on with Rivaroxaban consisted of 1.3% (n = 9) with hematomas requiring surgical evacuation, 0.43% (n = 3) with decreased hemoglobin requiring transfusions, and 0.1% (n = 1) with a DVT and pulmonary embolism. The complications encountered by 415 patients on with Apixaban consisted of 0.48% (n = 2) with a DVT. Novel oral anticoagulants (Rivaroxaban and Apixiban) are comparable to LMWH for chemical prophylaxis after body contouring procedures with similar rates of drug-related complications. Further investigation is warranted with more clinical cases in order to recommend the use of this medication for routine postoperative chemical prophylaxis after body contouring procedures. 3 Therapeutic" @default.
• W2296989445 created "2016-06-24" @default.
• W2296989445 creator A5012280042 @default.
• W2296989445 creator A5023622994 @default.
• W2296989445 creator A5038689037 @default.
• W2296989445 creator A5046769442 @default.
• W2296989445 creator A5048157170 @default.
• W2296989445 creator A5066361305 @default.
• W2296989445 creator A5085881021 @default.
• W2296989445 creator A5086791949 @default.
• W2296989445 date "2016-03-09" @default.
• W2296989445 modified "2023-10-18" @default.
• W2296989445 title "Safety and Efficacy of Novel Oral Anticoagulants vs Low Molecular Weight Heparin for Thromboprophylaxis in Large-Volume Liposuction and Body Contouring Procedures" @default.
• W2296989445 cites W101861224 @default.
• W2296989445 cites W102638144 @default.
• W2296989445 cites W1977327274 @default.
• W2296989445 cites W1980016336 @default.
• W2296989445 cites W1980954901 @default.
• W2296989445 cites W1982741996 @default.
• W2296989445 cites W1985842169 @default.
• W2296989445 cites W1989079090 @default.
• W2296989445 cites W1991761226 @default.
• W2296989445 cites W1994083919 @default.
• W2296989445 cites W1996398701 @default.
• W2296989445 cites W2001490631 @default.
• W2296989445 cites W2009550119 @default.
• W2296989445 cites W2014491911 @default.
• W2296989445 cites W2016481335 @default.
• W2296989445 cites W2020685892 @default.
• W2296989445 cites W2036506340 @default.
• W2296989445 cites W2036724855 @default.
• W2296989445 cites W2042750758 @default.
• W2296989445 cites W2063229586 @default.
• W2296989445 cites W2067118403 @default.
• W2296989445 cites W2077011253 @default.
• W2296989445 cites W2084412882 @default.
• W2296989445 cites W2090177155 @default.
• W2296989445 cites W2092608099 @default.
• W2296989445 cites W2103081453 @default.
• W2296989445 cites W2105320272 @default.
• W2296989445 cites W2114189419 @default.
• W2296989445 cites W2119697485 @default.
• W2296989445 cites W2133686162 @default.
• W2296989445 cites W2143431076 @default.
• W2296989445 cites W2150383508 @default.
• W2296989445 cites W2150567120 @default.
• W2296989445 cites W2151252098 @default.
• W2296989445 cites W2316631671 @default.
• W2296989445 cites W2324482888 @default.
• W2296989445 cites W4239204562 @default.
• W2296989445 doi "https://doi.org/10.1093/asj/sjv243" @default.
• W2296989445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26961988" @default.
• W2296989445 hasPublicationYear "2016" @default.
• W2296989445 type Work @default.
• W2296989445 sameAs 2296989445 @default.
• W2296989445 citedByCount "25" @default.
• W2296989445 countsByYear W22969894452016 @default.
• W2296989445 countsByYear W22969894452017 @default.
• W2296989445 countsByYear W22969894452018 @default.
• W2296989445 countsByYear W22969894452019 @default.
• W2296989445 countsByYear W22969894452020 @default.
• W2296989445 countsByYear W22969894452021 @default.
• W2296989445 countsByYear W22969894452022 @default.
• W2296989445 countsByYear W22969894452023 @default.
• W2296989445 crossrefType "journal-article" @default.
• W2296989445 hasAuthorship W2296989445A5012280042 @default.
• W2296989445 hasAuthorship W2296989445A5023622994 @default.
• W2296989445 hasAuthorship W2296989445A5038689037 @default.
• W2296989445 hasAuthorship W2296989445A5046769442 @default.
• W2296989445 hasAuthorship W2296989445A5048157170 @default.
• W2296989445 hasAuthorship W2296989445A5066361305 @default.
• W2296989445 hasAuthorship W2296989445A5085881021 @default.
• W2296989445 hasAuthorship W2296989445A5086791949 @default.
• W2296989445 hasBestOaLocation W22969894451 @default.
• W2296989445 hasConcept C126322002 @default.
• W2296989445 hasConcept C141071460 @default.
• W2296989445 hasConcept C2776265017 @default.
• W2296989445 hasConcept C2776301958 @default.
• W2296989445 hasConcept C2776884760 @default.
• W2296989445 hasConcept C2777557582 @default.
• W2296989445 hasConcept C2778661090 @default.
• W2296989445 hasConcept C2778959117 @default.
• W2296989445 hasConcept C2779161974 @default.
• W2296989445 hasConcept C2779662492 @default.
• W2296989445 hasConcept C2780290652 @default.
• W2296989445 hasConcept C2780638905 @default.
• W2296989445 hasConcept C2780868729 @default.
• W2296989445 hasConcept C42219234 @default.
• W2296989445 hasConcept C71924100 @default.
• W2296989445 hasConceptScore W2296989445C126322002 @default.
• W2296989445 hasConceptScore W2296989445C141071460 @default.
• W2296989445 hasConceptScore W2296989445C2776265017 @default.
• W2296989445 hasConceptScore W2296989445C2776301958 @default.
• W2296989445 hasConceptScore W2296989445C2776884760 @default.
• W2296989445 hasConceptScore W2296989445C2777557582 @default.
• W2296989445 hasConceptScore W2296989445C2778661090 @default.
• W2296989445 hasConceptScore W2296989445C2778959117 @default.
• W2296989445 hasConceptScore W2296989445C2779161974 @default.

• next